246 related articles for article (PubMed ID: 37616543)
1. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
[TBL] [Abstract][Full Text] [Related]
2. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
5. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B
BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
[TBL] [Abstract][Full Text] [Related]
7. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
8. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
Menzer C; Hassel JC
Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
[TBL] [Abstract][Full Text] [Related]
10. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
11. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA
Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485
[TBL] [Abstract][Full Text] [Related]
12. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
[TBL] [Abstract][Full Text] [Related]
13. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
15. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G; Neyns B
Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
[TBL] [Abstract][Full Text] [Related]
16. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
19. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
20. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
